• SSY Group won China NMPA production and registration clearance for choline fenofibrate sustained-release capsules (135 mg), a type 4 chemical drug.
• The approval is treated as passing China’s generic consistency evaluation, supporting commercialization in the lipid-lowering market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260716-12246293), on July 16, 2026, and is solely responsible for the information contained therein.